Labcorp Holdings Inc. (LH) Covered Calls

Labcorp (LH) is a leading global life sciences company providing vital diagnostic and drug development services. It operates an extensive clinical laboratory network, delivering routine and specialty testing for patients and healthcare providers. Additionally, its biopharma services segment supports pharmaceutical and biotech companies across the drug development lifecycle, from preclinical research to clinical trial management and commercialization.

You can sell covered calls on Labcorp Holdings Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for LH (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Labcorp Holdings Inc. (LH) operates as a diversified life sciences company with two primary business segments. The Diagnostics Laboratories segment provides a comprehensive menu of clinical laboratory tests, including routine blood chemistry, genomics, and advanced diagnostic testing, serving hospitals, physicians, and health systems globally. The Biopharma Laboratory Services segment provides end-to-end support for drug development, including preclinical, clinical, and central laboratory services, acting as a critical partner to the global pharmaceutical and biotechnology industries.

Labcorp’s business model is built on massive scale and deep integration into the healthcare value chain. By combining clinical diagnostic data with research capabilities, the company accelerates the development of new treatments and provides actionable insights for patient care. Its strategy focuses on leveraging digital technologies, AI-driven diagnostics, and strategic hospital partnerships to improve operational efficiency and expand its footprint in high-growth areas like oncology and precision medicine.

Competitive Landscape

Labcorp operates in a consolidated, high-barrier-to-entry market where scale and technical breadth are the primary competitive advantages. Key competitors include:

1. Quest Diagnostics (DGX): The most direct competitor in the U.S. clinical laboratory space. While Quest focuses heavily on domestic diagnostics, Labcorp differentiates through its significant, global Biopharma Laboratory Services business, which provides a unique revenue stream and closer integration with drug discovery and trial management.
2. IQVIA Holdings (IQV): A leader in clinical research and data analytics. IQVIA competes primarily with Labcorp’s Biopharma Laboratory Services segment. Labcorp competes by offering an integrated model that bridges clinical diagnostic insights with contract research organization (CRO) services, a combination that IQVIA does not address with the same diagnostic depth.
3. Charles River Laboratories (CRL): A specialized competitor focusing on early-stage, preclinical research and safety testing. Labcorp competes in the preclinical space while maintaining a much broader diagnostic portfolio, offering an integrated path from laboratory research to commercial patient diagnostics.

Strategic Outlook and Innovation

Labcorp is currently focusing on "LaunchPad" initiatives to drive operational excellence and margin expansion, while investing in specialty testing and hospital lab management agreements to build recurring, high-margin revenue. The company is also integrating AI into its pathology and diagnostic processes to increase test turnaround speed and accuracy, aiming to solidify its role as a premier health information partner.

Looking ahead, the company aims to sustain long-term growth by deepening its biopharma partnerships and expanding its precision medicine offerings. By maintaining a disciplined approach to capital allocation and continuously optimizing its global laboratory network, Labcorp intends to deliver consistent returns while remaining an essential partner in the global life sciences ecosystem.

Want more examples? LGND Covered Calls | LHX Covered Calls